Tuesday, March 1, 2011

ViewRay receives FDA 510(k) Marketing clearance for treatment planning and delivery Software


Main category: MRI/PET/ultrasound
Is also included In: medical devices/Diagnostics;  Radiology/nuclear medicine;  Regulatory Affairs/drug approvals
Article date: February 24, 2011-4: 00 PST window. fbAsyncInit = function () {FB. init ({appId: ' aa16a4bf93f23f07eb33109d5f1134d3 ', true, State: cookie: true, real, xfbml: channelUrl: ' http://www.medicalnewstoday.com/scripts/facebooklike.html '});}; (function() {var e = document.createElement("p") (' script '); e. async = true; and .src = document.location.protocol + '//' connect.facebook.net/en_US/all.js; document.getElementById (' fb-root ') appendChild (e);}()); email icon email printer icon to a friend write icon printer friendly views
not yet ratednot yet rated
ViewRay ™, Inc., a privately held medical device, received US FDA clearance for software planning and delivery of marketing of radiotherapy treatment. The software is a critical component of the system of the company new radiation therapy that combines magnetic resonance imaging and simultaneous delivery of radiation therapy. Now in the final stages of development, the integrated ViewRay is currently only available as a human being does not use the search system. The company is working at the FDA clearance for the commercial distribution system for clinical use.

"FDA clearance of our software represents a milestone in the development of the system," said ViewRay ViewRay President and CEO Gregory m. Ayers, MD, PhD. "in the past year ViewRay has achieved a remarkable success, string in funding and partnerships, and product development. It is exciting to see this progress with a product that we believe will offer an advance in radiotherapy ". ViewRay system is designed to provide continuous MRI soft tissue during cancer treatment, so that doctors can see exactly where the radiation is delivered.

ViewRay holds the exclusive license throughout the world for its combination of technology MRI and radiotherapy. The company recently secured $ 8 million in series c financing intended to move through the system of ViewRay final development and regulatory processes and towards marketing and positioning in major medical Center.

Source: ViewRay incorporated

Bookmark and Share

Note: any medical information published on this site is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we not publish your email address. It is used only to let you know when your message has been posted. We do not use it for other purposes. Please read our privacy policy for more information.

If you write about specific medicines or operations, please do not of professionals name by name.

All opinions are moderated before including (to stop spam)

Contact our News editorial

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical or health News News Releases:






View the original article here

No comments:

Post a Comment